TP53 and cancer: Accumulated evidence suggests that PARK7 can promote cancer cell death, survival, proliferation and metastasis by regulating redox balance, activating Akt/mTOR, MEK/ERK, NF-κB, and HIFα signaling pathways, or inhibiting p53, JNK, and ASK1 signaling pathways [22].